Evaluation of the Effectiveness, Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients
16 september 2013 uppdaterad av: Abbott
A Prospective, Multi-center, Post-marketing Observational Study to Evaluate the Effectiveness and Compliance of Ibuprofen in a Sustained Release Form in the Treatment of Egyptian Osteoarthritic Patients
This is a prospective, multi-center, post-marketing observational study to evaluate the effectiveness and compliance of ibuprofen in a sustained release form in the treatment of Egyptian osteoarthritic patients.
Studieöversikt
Status
Avslutad
Betingelser
Detaljerad beskrivning
This was a prospective, longitudinal, multicenter observational study conducted in a clinical practice setting where the study product was used in osteoarthritis patients as indicated in the approved package insert; the dosing regimen of Brufen retard is 2 tablets as a single dose once daily.
Studietyp
Observationell
Inskrivning (Faktisk)
519
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Alexandria, Egypten
- Site Reference ID/Investigator# 42584
-
Alexandria, Egypten
- Site Reference ID/Investigator# 42585
-
Alexandria, Egypten
- Site Reference ID/Investigator# 42591
-
Alexandria, Egypten
- Site Reference ID/Investigator# 42593
-
Alexandria, Egypten
- Site Reference ID/Investigator# 42594
-
Cairo, Egypten
- Site Reference ID/Investigator# 29755
-
Cairo, Egypten
- Site Reference ID/Investigator# 42582
-
Cairo, Egypten
- Site Reference ID/Investigator# 42583
-
Cairo, Egypten
- Site Reference ID/Investigator# 42586
-
Cairo, Egypten
- Site Reference ID/Investigator# 42587
-
Cairo, Egypten
- Site Reference ID/Investigator# 42588
-
Cairo, Egypten
- Site Reference ID/Investigator# 42589
-
Cairo, Egypten
- Site Reference ID/Investigator# 42590
-
Cairo, Egypten
- Site Reference ID/Investigator# 42592
-
Cairo, Egypten
- Site Reference ID/Investigator# 42595
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Testmetod
Icke-sannolikhetsprov
Studera befolkning
Primary care clinics
Beskrivning
Inclusion Criteria:
- Patients seeking treatment for osteoarthritis and there are clinical or radiological evidence of the disease,
- Male or female, age ≥ 18
- Designated to treatment with Ibuprofen in a sustained release form (Brufen Retard) according to the best criterion of the physician and if he decides to treat the patient according to labeled indication and dose for 4 weeks.
- Patients who have given their written informed consent to participate in the study
- Patients who are currently taking non steroidal anti inflammatory drugs (NSAIDs), should complete an initial washout phase 10 days depending on the half life of the drug taken
Exclusion Criteria:
- Contraindications as described in company core data sheet (CCDS) and specifically
- Patients with active peptic ulcer
- Patients who have presented reactions of hypersensitivity (asthma , rhinitis or urticaria ) with ibuprofen or other anti-inflammatory non steroids
- Patients with active cardiovascular disease and those taking aspirin/warfarin for prophylaxis for myocardial infarction (MI) or stroke
- Patients with moderate to severe renal diseases
- Patients with moderate to severe hepatic disease
- Patients with Crohn's disease
- Patients included currently in another study
- Women of childbearing potential must not be pregnant
- Any patients the investigators consider ineligible for this study
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
|---|
|
Osteoarthritic patients
Patients male or female, age ≥ 18 having clinical or radiological evidence of osteoarthritis
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Day and Night Mean Pain Score for the Previous 24 Hours on a Nine-point Scale (0 = no Pain to 8 = Very Severe Pain) at Visit 3 (4 Weeks Following Treatment) in Comparison to Baseline.
Tidsram: Baseline and 4 weeks
|
Scoring of day and night pain for the previous 24 hours was performed on a nine-point scale (0 = no pain to 8 = very severe pain) at each visit and compared to baseline.
The overall mean pain score was calculated for participants who completed the study at each visit.
|
Baseline and 4 weeks
|
|
Number of Participants Who Improved (Reduced Pain), Had no Change (Equal Scores at Baseline and Visit), and Worsened (Increased Pain) at Visit 3 (After 4 Weeks of Treatment).
Tidsram: 4 weeks
|
Scoring of day and night pain for the previous 24 hours was performed on a 9-point scale (0 = no pain to 8 = very severe pain) at each visit.
The number of participants at Visit 3 (after 4 weeks of treatment) who improved (had reduced pain; from higher baseline score to lower Visit 3 score), had no change (equal scores at baseline and Visit 3), and worsened (increased pain; from lower baseline score to higher Visit 3 score) was calculated.
|
4 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percent of Participant Compliance
Tidsram: 2 and 4 weeks
|
The frequency with which the participant forgot to take treatment or changed dose/administration was determined by comparing the actual number of tablets taken by the participant to the scheduled number of tablets since the last visit.
Results are presented in percent (0 - 100% scale, with 100% being perfect compliance and 0% being no compliance at all).
|
2 and 4 weeks
|
|
Number of Participants With Joint Tenderness/Stiffness at Each Visit
Tidsram: Baseline, 2 weeks, and 4 weeks
|
Joint tenderness/stiffness was measured using a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe) at each visit.
|
Baseline, 2 weeks, and 4 weeks
|
|
Number of Participants Who Improved (Reduced), Had no Change (Equal at Baseline and Visit), and Worsened (Increased) in Joint Tenderness/Stiffness at Visit 2 (After 2 Weeks of Treatment) and Visit 3 (After 4 Weeks of Treatment).
Tidsram: 2 and 4 weeks
|
Duration of morning stiffness at each visit was assessed and the number of participants who improved, had no change, or worsened at each visit, following 2 and 4 weeks of treatment (Visit 2 and Visit 3, respectively) was calculated.
|
2 and 4 weeks
|
|
Duration of Morning Stiffness
Tidsram: Baseline, 2 weeks, and 4 weeks
|
The duration of morning stiffness in minutes was assessed at each visit.
|
Baseline, 2 weeks, and 4 weeks
|
|
Number of Participants With 80% Reduction From Baseline in Duration of Morning Stiffness at Visit 2 (2 Weeks of Treatment) and Visit 3 (4 Weeks of Treatment)
Tidsram: 2 and 4 weeks
|
The number of participants who achieved an 80% reduction from baseline in morning stiffness was calculated at each visit.
|
2 and 4 weeks
|
|
Number of Participants With the Ability to Carry Out Normal Activities at Each Visit
Tidsram: Baseline, 2 weeks, and 4 weeks
|
The number of participants who were able or unable to carry out normal activities was assessed at each visit.
|
Baseline, 2 weeks, and 4 weeks
|
|
Number of Participants Who Experienced Adverse Events and Serious Adverse Events
Tidsram: Baseline to 4 weeks
|
Tolerability was assessed by collecting adverse events during the course of the study up to 30 days following the last dose of Brufen Retard.
The number of participants experiencing a serious or non-serious adverse event is summarized.
See the Reported Adverse Event section for details.
|
Baseline to 4 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 juni 2010
Primärt slutförande (Faktisk)
1 november 2010
Avslutad studie (Faktisk)
1 november 2010
Studieregistreringsdatum
Först inskickad
7 september 2010
Först inskickad som uppfyllde QC-kriterierna
20 oktober 2010
Första postat (Uppskatta)
21 oktober 2010
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
20 september 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
16 september 2013
Senast verifierad
1 januari 2012
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- P12-162
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .